Upcoming event


5α-Reductase inhibitors, Aanticoagulants, Antegrade ejaculation, Aquablation, Avanafil, Benign Prostatic Diseases, bipolar TURO, Bladder injury, Bladder outlet obstruction, Bladder trauma, BNC, BOO, BOOI, BPD, BPE, BPH, BPO, Chronic bacterial prostatitis, CP/CPPS, CPPS, Desmopressin, Detrusor, Detrusor hypocontractility, Dihydrotestosterone, Drug adherence, Drug therapy, Dutasteride, EAU, Ejaculation, Ejaculation preservation, Ejaculatory dysfunction, Endoscopic surgery, Epidemiology, Erectile dysfunction, Fexapotide triflutate, Fibrosis, Finasteride, Frequency volume chart, GL-XPS, GreenLight laser, Guidelines, Herbal medicines, HoLEP, Hypogonadism, Impaired contractility, Incontinence, Infertility, Inflammation, Inflammatory biomarkers, Innervation, IPP, IPSS, iTIND, Laparoscopy, Laser Bipolar, Laser prostatectomy, Laser therapy, LUT, LUTS, Major cardiac adverse event, Management of Non-Neurogenic LUTS incl. BPO, Medical therapy, Meta analysis, Meta regression, Metabolic syndrome, Microbiome, Micturition chart, Minimally invasive surgical therapy, minimally invasive techniques, Mirabegron, Monotherapies, Muscarinic antagonist, nitinol, Nocturia, Noninvasive, NX-1207, Overactive bladder, Pathogenesis, Pathophysiology, Patient satisfaction, Patient-reported outcome, Permixon, Pharmacology, Phenotypically directed multimodal management, Phosphodiesterase type 5 inhibitor, Phosphodiesterase type 5 inhibitors, Phytotherapy, Placebo effect, Plasmakinetic enucleation, Prospective study, Prostate, Prostate arterial embolisation, Prostate surgery, Prostate-specific antigen, Prostatectomy, Prostatic, Prostatic arterial embolization, Prostatic artery embolization, Prostatic hyperplasia, Prostatitis, PUL, Quality of life, Randomized trial, RASP, Remission, Retrograde ejaculation, Robotic, Robotic surgery, Robotics, Serenoa repens, Sexual Dysfunction, Sexual dysfunctions, Sildenafil, Simple prostatectomy, Solifenacin, Stem cells, Surgery, Surgical intervention, Systematic review, Tadalafil, Tamsulosin, Telomerase, Testosterone, ThuLEP, TmLRP, TUR syndrome, TURis, TURP, Ultrasonography, Underactive bladder, urethral implantable device, Urethral injury, Urethral trauma, Urinary Incontinence in Adults, Urinary nerve growth factor, Urinary sphincter, Urodynamics, Urolift, Vardenafil, Voiding, Voiding dysfunction, α-Adrenergic blocker, α-Adrenoceptor antagonists, α-Blocker, α-blockers, α1-Blockers
Show all

Impact on sexual function of endoscopic enucleation versus transurethral resection of the prostate for lower urinary tract symptoms due to benign prostatic hyperplasia: A systematic review and meta‑analysis

Highly biased and misleading: Information on surgical treatment of benign prostatic hyperplasia on YouTube

Assessment of bladder outlet obstruction in men: A new diagnostic model based on non-invasive urodynamic parameters

Efficacy and safety of combination treatment with tadalafil and mirabegron for persistent storage symptoms despite tadalafil treatment in patients with benign prostatic hyperplasia

A randomized trial comparing bipolar transurethral vaporization of the prostate with GreenLight laser (xps‐180watt) photoselective vaporization of the prostate for treatment of small to moderate benign prostatic obstruction: outcomes after 2 years

BJU International, Volume 125, Issue 1, January 2020, Pages 144-152

Ejaculatory hood-sparing photoselective vaporization of the prostate vs bipolar button plasma vaporization of the prostate in the surgical management of benign prostatic hyperplasia

Journal of Endourology, Volume 34, Issue 3, March 2020

Thulium laser enucleation versus thulium laser resection of the prostate for prevention of bladder neck contracture in a small prostate: a prospective randomized trial

World Journal of Urology, Volume 37, Issue 5, May 2020, Pages 853-859

Holmium laser enucleation vs bipolar plasmakinetic enucleation of a large volume benign prostatic hyperplasia: a randomized controlled trial

Journal of Endourology, Volume 34, Issue 3, March 2020

Predictive factors of urinary incontinence after holmium laser enucleation of the prostate: a multicentric evaluation

World Journal of Urology, March 2020

Mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: a randomized, placebo-controlled study (MATCH)

European Urology Focus, November 2020

Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo

European Urology, January 2020

A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study)

Neurourology and urodynamics, February 2020